

MGB Biopharma Fully Supports the Latest Report from Jim O’Neill’s Review on Antimicrobial Resistance

Glasgow, Scotland, 15th May 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, endorses the latest report from Jim O’Neill’s Review on Antimicrobial Resistance and welcomes the idea of a global AMR Innovation fund.

Dr Miroslav Ravic, CEO of MGB Biopharma, said: “We are pleased that the major problem of antimicrobial resistance is now receiving the attention it clearly deserves. The figures contained in Jim O’Neill’s report, and in particular the potential human cost of not addressing antibiotic resistance, are alarming. The need for novel and differentiated products to tackle antimicrobial resistance is clear and requires new and radical thinking from a broad range of stakeholders. Reflecting the challenges of antibiotic development, MGB Biopharma is one of the very few companies in the world developing a truly novel class of antibiotics that have been designed to tackle the infections caused by resistant bacterial pathogens. Our lead antibiotic candidate MGB-BP-3, which is active against a range of multi-resistant Gram-positive pathogens, is about to enter a Phase I clinical study and could be available to patients within the next three years.”

MGB Biopharma would hope to benefit from the Global AMR Innovation fund, proposed by Jim O’Neill, as it works to bring MGB-BP-3 to the market in a timely fashion, and become one of the first truly novel classes of antibiotic, with no prior resistance, to be approved in over ten years.

MGB Biopharma has completed preclinical development of an oral formulation of its lead compound MGB-BP-3 for the treatment of *Clostridium difficile* infections. This novel antibiotic is due to start a Phase I study shortly. Work to-date with MGB-BP-3 has shown that it has a number of potential advantages over vancomycin which could yield important clinical benefits when treating patients with *Clostridium difficile* infections.

In addition, MGB Biopharma is developing an intravenous formulation of MGB-BP-3 for hospital acquired systemic Gram-positive infections and this is expected to be IND-ready by the end of 2015. The IV formulation has shown potent bactericidal activity against some of the most important Gram-positive pathogens including MRSA and *Streptococcus* spp, in a range of preclinical infection models. The Company is also planning to complete a feasibility study with a topical formulation of MGB-BP-3 by the end of the summer, 2015.

MGB Biopharma’s anti-infectives are generated from its truly novel DNA minor groove binder technology platform which was originally developed at the University of Strathclyde. MGB-based anti-infectives have the potential to deliver significant advantages over current approaches based on broad, bactericidal activity against multi-drug resistant Gram-positive pathogens. Other compounds from the platform have shown the potential to treat infection caused by Gram-negative, viral, fungal and parasitic organisms.

MGB Biopharma activities to-date have been funded by a number of Scottish investors including Archangel Investors, Barwell, TRI Cap and the Scottish Investment Bank, Scottish Enterprise. In 2014, the Company also received an award from Innovate UK under the Biomedical Catalyst competition.



MGB Biopharma

For further information, please contact:

MGB Biopharma

Miroslav Ravic, Chief Executive Officer
Adam Christie, Chairman,
Or
Dr Dawn Firmin, Head of Project Management
enquiries@mgb-biopharma.com
+44 (0) 208 946 0120

Citigate Dewe Rogerson

David Dible/Sylvie Berrebi

david.dible@citigatedr.co.uk

+44 (0) 20 7282 2949

About MGB Biopharma

MGB Biopharma is developing a truly novel class of anti-infectives. Its lead candidate, MGB-BP-3, is an antibacterial which is active against a broad range of important multi-resistant Gram-positive pathogens. The Company has developed an oral formulation of MGB-BP-3 for the treatment of *Clostridium difficile* that is ready to enter the clinic, whilst an intravenous formulation targeting the treatment of a range of systemic hospital acquired Gram-positive infections is in late-stage preclinical development.

MGB Biopharma has close links with the University of Strathclyde, with exclusive worldwide licence rights to the University's MGB patents for all fields except anti-cancer. The Company intends to work with partners to fully capitalise on the multiple value creating opportunities offered by its broad and novel anti-infectives platform.

The Company was founded in 2010 and is headquartered in Glasgow, Scotland. It is backed by Scottish investors including Archangel Investors, Barwell, TRI Cap and the Scottish Investment Bank, Scottish Enterprise. For more information please visit www.mgb-biopharma.com.